Immunoglobulin Therapy

Professional Activities

1982 – present Investigator, Consultant, Advisor, Speaker for ADMA Biologicals, Baxter/Baxalta/Shire/Takeda, Sandoz/ZLB, CSL/CSL Behring, Kedrion, Miles/Bayer/Talecris/Grifols, Prometic, Therapure/Evolve Biologicals 

1987 – present Clinical Immunology Society member, Fellow 2021 to present 

1992 – 2025 65 peer-reviewed immunoglobulin therapy publications 

1996 – present AAAAI Primary Immunodeficiency Diseases Committee 

1999 – 2025 35 immunoglobulin therapy studies

Bibliography 2000-2025

  • Wasserman, R.L. Clinical Practice Experience with HyQvia in Adults Using Alternative Dosing Regimens and Pediatric Patients: A Retrospective Study. 2020. Adv Ther 37, 1536–1549. https://doi.org/10.1007/s12325-020-01264-7 

  • Perez EE, Jacques H, Ellis AK, Alpan O, Lumry WR, Shapiro R, Suez D, Mandujano J F, Wasserman RL. Efficacy, Safety and Tolerability of a New 10% Intravenous Immunoglobulin for the Treatment of Primary Immunodeficiencies. Frontiers in Immunology. 12:2728. 2021 DOI=10.3389/fimmu. 2021.707 

  • Wasserman, RL, Gupta S, Stein M, et al. Infection rates and tolerability of three different immunoglobulin administration modalities in patients with primary immunodeficiency diseases. 2021. Immunotherapy. https://doi.org/10.2217/imt-2021-0256

  • Wasserman RL. Immunoglobulin Replacement Therapy Stewardship in Modern Times. 2022. Ann Allergy, Asthma, Immunol.  DOI: https://doi.org/10.1016/j.anai.2022.05.002.

  • Wasserman RL, Cunningham-Rundles C, Anderson J, Lugar P, Palumbo M, Patel NC, Hofmann J, Rogers E, Praus M, Rojavin M. Systemic IgG Exposure and Safety in Patients with Primary Immunodeficiency: a Randomized Crossover Study Comparing a Novel Investigational Wearable Infusor Versus the Crono Pump. 2022. https://doi.org/10.2217/imt-2022-0097.

  • Wasserman RL. Reply to High Cost of Immunoglobulin Replacement Therapy: Causes and Implications. 2022. Ann Allergy, Asthma, Immunol.  DOI:https://doi.org/10.1016/j.anai.2022.11.005

  • Patel NC, Walter J, Wasserman RL, Rubinstein A, Kankirawatana S, Shepherd M, Greco M, Li M, Russo Schwarzbaum S, Shumyla Khawaja S, McCoy B, Yel L. Efficacy and safety of hyaluronidase-facilitated subcutaneous immunoglobulin 10% in US pediatric patients with primary immunodeficiency disease. 2023, Clin Immunol. 250, Suppl,2023,109598,ISSN 1521-6616, https://doi.org/10.1016/j.clim.2023.109598

  • Tzivelekis S, Orange J, Poulos C, Meckley LM, Peay H, Sutphin J, Hernandez-Trujillo VP, Wasserman RL. Development of a novel shared decision making aid for primary immunodeficiency diseases. Immunotherapy. 2023;15:647-656. doi: 10.2217/imt-2022-0193. Epub 2023 May 9. PMID: 37158075.

  • Rubinstein A, Mabudian M, McNeil D, Patel NC, Wasserman RL, Gupta S, Carrasco P, Nagy A, Chen J, Garcia E, Yel L. Long-term safety of facilitated subcutaneous immunoglobulin 10% treatment in US clinical practice in patients with primary immunodeficiency diseases: results from a post-authorization safety study. J Clin Immunol 2024;44:181. doi.org/10.1007/s10875-024-01769-8.

  • Patel NC, Walter J, Wasserman RL, Rubinstein A, Kankirawatana S, Shepherd M, Greco M, Li M, Russo Schwarzbaum S, Shumyla Khawaja S, McCoy B, Yel L. Efficacy, Safety, Tolerability, and Serum IgG Trough Level Profiles of Hyaluronidase-facilitated Subcutaneous Immunoglobulin 10% in US Pediatric Patients with Primary Immunodeficiency Diseases. 2025. J Clin Immunol; 45:81.    https://doi.org/10.1007/s10875-025-01862-6